ArticleBritish journal of cancer2005
DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.Oncotarget · 2017Pooled it
- Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.Drug design, development and therapy · 2015Pooled it
- Clinicopathological significance and potential drug target of RUNX3 in breast cancer.Drug design, development and therapy · 2014Pooled it
- Review
- RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018Article
- The roles of RUNX3 in cervical cancer cellsOncology letters · 2018Article
- Endometriosis and Ovarian Cancer: an Integrative Review (Endometriosis and Ovarian Cancer)Asian Pacific journal of cancer prevention : APJCP · 2017Article
- BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis.OncoTargets and therapy · 2016Article
- Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.The Prostate · 2016Article
- Inactivation of RUNX3 predicts poor prognosis in esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.Medical oncology (Northwood, London, England) · 2014Article
- Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis.Journal of thoracic disease · 2014Article
- Review
- Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.Journal of gastroenterology · 2013Article
- RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line.OncoTargets and therapy · 2013Article
- Generation and characterization of Tmeff2 mutant mice.Biochemical and biophysical research communications · 2012Article
- Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer.Molecules and cells · 2012Article
- TGF-β mediated DNA methylation in prostate cancer.Translational andrology and urology · 2012Article
- Tumor suppressor function of RUNX3 in breast cancer.Journal of cellular biochemistry · 2012Article
Corrections and comments
- Retraction · 2013-12-10Duplication of/in Image · Investigation by Company/Institution · Manipulation of Images · Misconduct by Author ·
- Commented on by
- Commented on by
- Retracted
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transforming growth factor beta (TGFbeta)-signalling pathway is deregulated in many cancers. We examined the role of gene silencing via aberrant methylation of DRM/Gremlin and HPP1, which inhibit TGFbeta signalling, and RUNX3, which facilitates TGFbeta-signalling, of all genes that are thought to be tumour suppressors, are aberrantly expressed, and are thus thought to have important role in human cancers. We examined DRM/Gremlin mRNA expression in 44 cell lines and the promoter methylation status of DRM/Gremlin, HPP1, and RUNX3 in 44 cell lines and 511 primary tumours. The loss of DRM/Gremlin mRNA expression in human cancer cell lines is associated with DNA methylation, and treatment with the methylation inhibitor-reactivated mRNA expression (n=13). Methylation percentages of the three genes ranged from 0-83% in adult tumours and 0-50% in paediatric tumours. Methylation of DRM/Gremlin was more frequent in lung tumours in smokers, and methylation of all three genes was inversely correlated with prognosis in patients with bladder or prostate cancer. Our results provide strong evidence that these TGFbeta-related genes are frequently deregulated through aberrant methylation in many human malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.